Does TRT Cause Prostate Cancer? A Urologist Explains
Almost every man I start on testosterone asks the same thing first: will this give me prostate cancer? Here's what the saturation model and the TRAVERSE trial actually tell us.
Does TRT cause prostate cancer? It is the first question almost every man asks me before he starts testosterone, and it is a fair one — for decades, doctors themselves believed the answer was yes. That belief came from a single set of experiments done in 1941, long before we had blood tests, modern imaging, or a single randomized trial. The science has moved a long way since then, and the short version is reassuring, but it comes with real conditions you need to understand. For the wider picture on prostate health, you can also see our Prostate Health Hub. This article walks through where the fear came from, what the saturation model and the 2023 TRAVERSE trial actually show, and exactly when testosterone therapy still needs a urologist’s caution first.
Key Takeaways
- The fear that testosterone “feeds” prostate cancer comes from 1941 castration studies in men who already had advanced cancer — not from men with normal prostates starting therapy.
- The saturation model explains why adding testosterone above roughly 150–250 ng/dL does little to the prostate: the androgen receptors are already full.
- In the TRAVERSE trial of about 5,200 men, testosterone therapy did not raise the rate of prostate cancer compared with placebo.
- TRT can nudge your PSA up modestly and may unmask a cancer that was already there — which is why monitoring, not avoidance, is the right response.
- Men with a prostate cancer history, an abnormal exam, or a PSA above 4 ng/mL need a urologist’s assessment before starting, not a blanket “no.”
Where the testosterone-cancer fear actually came from
In 1941, Charles Huggins and Clarence Hodges showed that lowering testosterone — by castration or estrogen — shrank advanced, metastatic prostate cancer, while giving testosterone made it grow. The work was important enough to earn a Nobel Prize, and it is still the basis for hormone therapy in advanced disease today. The problem was the leap that followed: if removing testosterone shrinks late-stage cancer, then surely adding testosterone must cause cancer in healthy men. That assumption hardened into medical dogma for over sixty years.
Two details got lost along the way. First, Huggins studied men who already had widespread cancer, not men with healthy prostates. Second, his patients had been surgically castrated to near-zero testosterone — a world away from a man whose level sits at 200 ng/dL (6.9 nmol/L) and wants to feel normal again. Applying findings from castrate-level disease to a man with simple testosterone deficiency was a category error, and an entire generation of men paid for it by being denied treatment.
The saturation model: why more testosterone isn’t more fuel
The piece that finally made sense of the contradiction is the saturation model, described by Abraham Morgentaler and Abdulmaged Traish in 2009. Testosterone acts on the prostate by binding to a fixed number of androgen receptors inside prostate cells. Think of those receptors like parking spaces in a small lot: once every space is full, more cars arriving on the street outside change nothing. The lot is already at capacity.
Those receptors fill up — saturate — at a serum testosterone of roughly 150 to 250 ng/dL (about 5 to 8.7 nmol/L), which is below the normal male range. The prostate is genuinely sensitive to testosterone below that point, which is exactly why castration shrinks cancer. But pushing a man from a deficient 200 ng/dL up to a healthy 600 ng/dL (20.8 nmol/L) is adding cars to a lot that is already full. This is the mechanical reason testosterone therapy does not behave like fertilizer for the prostate, and it lines up with what we actually see in the clinic and in trials.
In My Practice
A 52-year-old came to me exhausted, with a testosterone of 210 ng/dL and a completely normal PSA, but he had refused treatment for two years because his father had prostate cancer and he was certain testosterone would “feed” it. When we finally started therapy and his PSA stayed flat across eighteen months of monitoring, the relief on his face told me more than any trial could.
Most of the fear I meet is inherited from a 1940s idea, not from the man’s own numbers — and the right answer is almost always careful monitoring, not avoidance.
Does TRT cause prostate cancer? What the modern evidence shows
The strongest data we have is the TRAVERSE trial, published in 2023. About 5,200 men, average age 63, with testosterone deficiency were randomly assigned to testosterone gel or placebo and followed for prostate outcomes [2]. The result: the rate of any prostate cancer, and of high-grade prostate cancer, was low and showed no significant difference between the testosterone and placebo groups [3]. This is the largest randomized trial ever done on the question, and it directly contradicts the old fear.
This is also why the American Urological Association’s testosterone guideline tells clinicians to inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer — graded as a strong recommendation [1]. That is unusually firm language for a medical guideline, and it reflects how consistent the modern data has become.
Here is the honest caveat, because it matters: TRAVERSE deliberately excluded men who already had a PSA above 3.0 ng/mL or known prostate cancer. So the trial proves testosterone therapy is safe for the prostate in men who start with a normal PSA and no cancer — it does not prove safety for a man with an elevated PSA or an untreated tumor. That distinction is the whole reason the assessment before you start is not a formality.
Not sure your testosterone symptoms are what they seem? Download Dr. Khalid’s Low Testosterone Testing & Treatment Guide.
Enter your email below to receive Dr. Khalid’s complete Low Testosterone: Testing & Treatment Guide as a free, printable PDF.
TRT, PSA, and what actually needs watching
Testosterone therapy usually causes a small, early rise in PSA — often a fraction of a point — as the prostate returns to its normal hormonal baseline. That bump is expected and is not a cancer signal by itself. What we watch for is the pattern: a confirmed PSA that keeps climbing, or a rise of more than roughly 1.4 ng/mL within the first year, is the change that earns a closer look. The testosterone is not the villain here — it is acting like a stress test that can reveal a cancer that was already present and silent.
This is why I never start a man over 40 on testosterone without a baseline PSA and a prostate exam first. If your number lands in the ambiguous 4–10 ng/mL band, our guide on what a PSA in the grey zone really means walks through how that gets interpreted. And if you are not yet on therapy but want to understand your own screening timeline, the age-by-age breakdown in our prostate cancer screening guide is the place to start. You can also run your own number through the PSA Age-Adjusted Interpreter to see how it reads against your age band.
The American Urological Association recommends checking testosterone every 6 to 12 months on therapy [1]. In practice I pair that with PSA monitoring: baseline before starting, again at around 3 to 6 months, then at 12 months, and yearly after that. Steady numbers across that schedule are exactly what we expect to see — and almost always what we do see.
When TRT genuinely needs caution
“Testosterone does not cause prostate cancer” is not the same as “testosterone is safe for everyone, no questions asked.” The reassurance applies to men who start with a healthy prostate. Several situations change the conversation and call for a urologist before a single dose. A man considering therapy should also read our full guide to what I tell patients before starting TRT, which covers the wider risks beyond the prostate.
Men with a previously treated prostate cancer are not automatically excluded — the AUA guideline supports considering testosterone on a case-by-case basis after treatment, with full transparency that long-term data is still limited [1]. That is a shared decision between you and your urologist, not a self-service one. If you want a sense of your baseline risk before that conversation, the Prostate Cancer Risk Calculator gives a structured estimate to bring with you.
See a Urologist Before Starting Testosterone If You Have
These do not necessarily rule out therapy, but they must be assessed and cleared first — not worked around:
- A PSA above 4 ng/mL, or a PSA that has been rising on recent tests
- A firm area, nodule, or asymmetry felt on a prostate exam
- A personal history of prostate cancer, treated or untreated
- A strong family history of prostate cancer (father or brother, especially before age 65)
- New or worsening urinary symptoms alongside a changing PSA
Frequently Asked Questions
Does TRT cause prostate cancer if I have no history of it?
Based on current evidence, no. The TRAVERSE trial of around 5,200 men found no rise in prostate cancer with testosterone therapy versus placebo, and the AUA guideline states there is an absence of evidence linking the two. That reassurance applies to men who begin therapy with a normal PSA and prostate exam, which is why that baseline check is done before you start.
Will testosterone therapy raise my PSA?
Often a little. Most men see a small, early PSA rise as the prostate returns to its normal hormonal state, and that is expected. What matters is the trend over time, not the initial bump. A confirmed steady climb, or a rise of more than roughly 1.4 ng/mL in the first year, is what prompts a urology review rather than the testosterone itself.
Can I take TRT if I’ve already been treated for prostate cancer?
Possibly, but only as a case-by-case decision with your urologist. The AUA guideline supports considering testosterone in men with treated prostate cancer while being clear that long-term safety data remains limited. This is not a decision to make alone or through an online clinic — it needs a specialist who knows your cancer details and monitors you closely.
How often should my PSA be checked while on testosterone?
I check PSA at baseline before starting, again at around 3 to 6 months, at 12 months, then yearly. The AUA recommends measuring testosterone every 6 to 12 months on therapy, and I pair PSA with those visits. You can see how your individual result reads against your age band using our PSA Age-Adjusted Interpreter.
Does a higher testosterone level mean a higher prostate cancer risk?
No. The saturation model explains why: prostate androgen receptors fill up at roughly 150 to 250 ng/dL, so raising a deficient man into the normal range adds testosterone the prostate cannot use. Studies do not show that men with naturally higher testosterone get more prostate cancer, and pushing a low level up to normal does not behave like adding fuel.
References
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. AUA
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. NEJM
- Bhasin S, Travison TG, Pencina KM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(12):e2347917. PubMed Central
- Morgentaler A, Traish AM. Shifting the Paradigm of Testosterone and Prostate Cancer: the Saturation Model and the Limits of Androgen-Dependent Growth. Eur Urol. 2009;55(2):310-320. PubMed
Dr. Muhammad Khalid
MBBS · FCPS (Urology) · MCPS (Gen. Surgery) · CHPE · CRSM · IMC #539472
Specialist urologist with 11+ years of clinical experience across tertiary teaching hospitals. Trained at Lady Reading Hospital and Khyber Teaching Hospital, Peshawar. Author of 5 peer-reviewed international publications in Cureus, WJSA, and AJBS. Procedural expertise: URS, PCNL, RIRS, TURP, TURBT, and major open urological surgery. Full profile →
This article is for educational purposes only and does not constitute medical advice. Always consult your physician or urologist for diagnosis and treatment decisions specific to your condition.
